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The Chinese Academy of Sciences held its 7th forum on 
frontiers of Science and Technology, April 12–13, 2012, in 
the academy hall of the Chinese Academy of Sciences. The 
Forum was organized by the Life Science and Medicine 
Division and co-organized by Academy of Military Medical 
Sciences and Science China Press. The theme of the 7th 
Forum was “Lifeomics and Translational Medicine”, and 
the purpose was to discuss the significance of lifeomics (i.e., 
genomics, RNAomics and proteomics) in life sciences, to 
examine the current status, and identify the trends of 
lifeomics, to promote inter-disciplinary collaboration and  
transformation, and to stimulate international academic ex-
changes and cooperation. An unprecedented number of 12 
academicians participated in the forum. They were Acade-
micians Qiang BoQin, He FuChu, and Zeng YiXin, Shi 
YunYu, Chen KaiXian, Zhao GuoPing, He Lin, Chen 
RunSheng, Chen XiangMei, Yang HuanMing, Cheng Jing, 
and Zhang XueMin. Academicians Qiang BoQin, He 
FuChu, and Zeng YiXin served as co-chairs, Other partici-
pants included Profs. Wu JiaRui, Zhu WeiMin, Wang Jun, 
Han JingDong, Chen Biao, Han ZeGuang, He DaCheng, 
Jiang Ying, Li Dong, Liang SongPing, Liu ShaoJun, Liu 
SiQi, Liu YinKun, Luo JingChu, Peng XiaoZhong, Qian 
XiaoHong, Qin Jun, Qu LiangHu, Sun Wei, Wang Jian, Wei 
KaiHua, Xu Ping, Yang XiaoMing, Zhao ShiMin, Zhou 
GangQiao, Zhu JingDe, and Zhu YunPing, all of whom are 
leaders in this field. The forum attracted more than 200 ex-
pert attendees.  
At the start of the forum, 15 well-known experts in 
lifeomics and translational medicine delivered excellent 
seminars focusing on “the rapid development of lifeomics”, 
“lifeomics and bioinformatics” and “lifeomics and transla-
tional medicine”. They reviewed the current status of ge-
nomics, RNAomics and proteomics. The Forum fostered 
discussions on advancing the application of the prospering 
lifeomics and translational medicine to help better under-
stand the biology behind human diseases. At the second 
stage of the forum, discussions, dubbed “brainstorming”, 
focused on the status quo and the developmental trends of 
lifeomics in the future, bioinformatics, as well as the com-
bination of lifeomics and translational medicine.  
After the brainstorming discussion, experts reached con-
sensus on the following: (i) lifeomics (genomics, RNAom-
ics and proteomics) would still be a new scientific discipline, 
employing unique epistemology and methodology, and 
quickly becoming the thrust of life sciences. Lifeomics 
would bring new perspective for life sciences and medical 
research and would be therefore, of significant value with 
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an excellent prospect in application; (ii) lifeomics technolo-
gies based on high-throughput gene sequencing and biolog-
ical mass spectrometry were set to open up new avenues of 
research and to usher in a new era of discovery in life sci-
ences. The ever-advancing lifeomics technologies would 
certainly speed up the output rates, quality and accuracy of 
large-scale quantitative omics data, providing us with 
oceans of data, but would also bring forward some new is-
sues, such as individual differences and personalized medi-
cine, environmental factors and epigenetics and diseases, 
omics and evolution; (iii) standardization of the omics in-
formation and capabilities of in-depth data mining would 
become current technological bottlenecks. What was ur-
gently needed was to address those issues by both techno-
logical and scientific mechanisms; (iv) lifeomics and trans-
lational medicine had forged a preliminary unification, 
started exploration in mechanisms, diagnosis and treatment 
of complex diseases such as cancer, diabetes, and hepatitis. 
Participating experts also presented some of their own 
views about lofeomics and suggested ways to manage the 
research in omics. As for how to develop lifeomics strate-
gically, the following were recommended: (i) the main tasks 
of lifeomics would be to describe the phenomenon of life, to 
investigate the physiological mechanisms, and to apply the 
omics in medicine and human health. Three stages of lifeom-
ics development were envisioned, which were technology 
development, functional studies, and translational medicine; 
(ii) the study of lifeomics in China was generally fragment-
ed, lacking cohesion. It would be of great importance that 
research efforts be coordinated to facilitate effective com-
munication and integration amongst research institutions 
and between research institutions and hospitals; (iii) we 
should engage in lifeomics research with Chinese character-
istics, for example, omics in traditional Chinese medicine, 
and systems biology of stem cell differentiation induciton.  
As to the scientific prospects of lifeomics, some partici-
pants believed that we should focus on (i) the impact of 
various types of modification on the function of biomole-
cules (i.e. DNA, RNA, and protein); (ii) omics research on 
cancer and other complex diseases, including the relation-
ship between the tumor and the evolution, cancer and aging, 
and new cancer treatment targets; (iii) the interaction omics, 
including expanded protein-protein interaction networks, 
the interaction of protein with other molecules, signaling 
network function and regulation, and network pharmacolo-
gy; (iv) comprehensive study of lifeomics with an aim to 
integrate genomics and RNA-omics with proteomics, gly-
comics and metabolomics; (v) preliminary exploration on 
personalized treatment with minimizing the costs in mind.  
Experts at the Forum also believed that our research ef-
forts should address the following: (i) establishing bioin-
formatics data standards and data management centers; In 
omics research, China was not lagging behind but leading 
the world in some aspects. However, in data standards and 
management, there was a large gap between China and the 
developed countries in Europe and the United States. The 
quantity and quality of the data fell short of the research 
needs. Besides, the variety of quality standard format and 
the lack of sharing mechanisms further hindered our pro-
gress. Priority must be given to developing data standards, 
data submission and sharing mechanisms, and to building 
bioinformatics service platforms for multi-omics research; 
(ii) omics service platforms. Omics in China was still at the 
stage where each research team still had the mindset of do-
ing everything themselves, which to some extent affected 
the quality control and public sharing of data. The urgent 
need would be to make full use of excellent teams in order 
to strengthen the open services and to promote the optimal 
allocation and efficient use of scientific resources; (iii) hu-
man cohort. Human cohort would not only be an important 
resource for functional omics research but could also serve 
as a bridge between bench and bed; (iv) omics of model 
organisms, especially primates. Studies of model organisms 
would prepare us for human omics research.  
The large-scale nature of omics research brings in man-
agement issues including how to finance the projects. The 
recommendations are as follows: (i) we should take ad-
vantage of our tradition in big projects to initiate a major 
omics project with academician He FuChu serving as the 
chief scientist. Research efforts of national teams with ex-
cellence in genomics, RNAomics and proteomics would be 
coordinated to focus on pressing scientific issues; (ii) an 
coordinated thinking and planning would be necessary to 
reflect the ultimate goal of lifeomics and current technical 
status. Top-down design of research policies and programs 
were in need and implementing research programs in stages 
was recommended; (iii) centering around major diseases, 
large research teams should be established integrating re-
search institutions and hospitals; (iv) innovation in the 
mechanisms assessing research institutions, universities 
and colleges, and  hospitals would be necessary in order 
to promote translational medicine; (v) innovation in man-
agement mechanisms for omics service centers, especially 
data centers, would be a must in order to have better and 
open service, to have better quality control over data col-
lection, and sharing.  
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